# A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis

> **NCT03178487** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 187 (actual)

## Conditions studied

- Ankylosing Spondylitis (AS)

## Interventions

- **DRUG:** Upadacitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03178487
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-24
- **Primary completion:** 2019-01-21
- **Final completion:** 2022-02-17
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2023-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03178487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03178487, "A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03178487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*